Navigation Links
WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
Date:5/6/2008

Earnings Conference Call to be held on May 28, 2008 at 8:00 am (Eastern) /

5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong)

SHANGHAI, China, May 6 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it will release unaudited financial results for the first quarter 2008 after the US market close on Tuesday, May 27, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Wednesday, May 28, 2008 to discuss its 2008 first quarter financial results and recent business activity. The conference call may be accessed by calling:

Toll Free Toll

United States +1 718-354-1389

Hong Kong +852 3002-1356

A telephone replay will be available shortly after the call until June 26, 2008 at (US) +1 866-883-4489, +1 718-354-1112 / (HK) +852 3002-1607. Passcode: 5274714#.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi, Vice President,

Corporate Communications

WuXi PharmaTech Co., Ltd.

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Investor Relations (HK):

Ruby Yim, Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: Pharmatechs@taylor-rafferty.com

Media Contact:

John Dudzinsky, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
2. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
3. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
4. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
5. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
6. WuXi PharmaTech Completes Acquisition of AppTec
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
9. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
10. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... , March 22, 2017  UBM and ... to announce their extended partnership and the third ... headlined by the 21 st Annual MassMEDIC ... taking place May 3-4, 2017. ... Technology Association (ADVAMED) President and CEO, Scott ...
Breaking Biology Technology:
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
Breaking Biology News(10 mins):